“… 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 These studies vary in the number of individuals with MS who were followed from 7 22 to 60. 27 Other studies used targeted or untargeted serum metabolomics to identify metabolites that are altered in individuals with MS compared with healthy controls (their main findings are shown in Table S1 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 ) or to distinguish MS from other neurological diseases. 39 , 40 , 41 …”